Respiratory syncytial virus (RSV) immunisation RSV prevention resources and data to assist healthcare providers and the general public RSV – frequently asked questions (FAQs) RSV immunisation products – evaluation and expected access RSV immunisation products – efficacy and safety NCIRS webinar: RSV and older adults NCIRS webinar: RSV and infants Useful links ATAGI statement on nirsevimab 2024 – Australian Government Department of Health and Aged CareATAGI statement on the clinical use of Arexvy (RSV PRE-F3) vaccine for RSV – Australian Government Department of Health and Aged CareArexvy: Australian prescription medicine decision summary – TGABeyfortus: Australian prescription medicine decision summary – TGABeyfortus (nirsevimab) guidance:NSW HealthQueensland HealthWA HealthRSV clinical trial tracker – PATH News & events News | 28 June 2024 Call for participants: new NCIRS study on possible links between genes and adverse events after COVID-19 vaccination News | 28 June 2024 NCIRS associate director awarded NHMRC and MRFF grants News | 21 June 2024 NCIRS expert attends advanced vaccinology course in France News | 30 May 2024 New study launched to increase Q fever vaccine eligibility for more children in Australia 809 views